Daniel Drucker
Daniel Drucker is a Canadian scientist credited with identifying GLP-1, the peptide that underlies the mechanism of Ozempic, and he predicts that future developments will make these weight loss medications more accessible.
Born on Jan 01, 1955 (71 years old)
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 2 | 8.50 | 0.33% | +0% | 38,005,238 | 124,812 | $1,700,000 | 5,583$ |
| Totals | 2 | 38,005,238 | 124,812 | $1,700,000 | 5,583$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Dr. Daniel Drucker is best known for helping to discover the class of drugs that includes Ozempic.
8
Canada:
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug.
9
Canada:
Dr. Daniel Drucker is a senior investigator at the Lunenfeld-Tanenbaum Research Institute and a pioneer of GLP-1 science.
9
Canada:
Canadian scientist Daniel Drucker played a key role in the discovery of GLP-1 drugs.
8
Slovenia:
Daniel Drucker is a Canadian endocrinologist known for his contributions to the development of the weight loss drug Ozempic.
8
Spain:
Daniel Drucker was awarded for fundamental biological discoveries that led to new effective drugs for diabetes and obesity.
9
Spain:
Daniel Drucker is a Canadian endocrinologist who has significantly contributed to the understanding of GLP-1 and its implications for obesity treatment.
9
Canada:
Dr. Daniel Drucker was among five researchers jointly awarded a US$3-million Breakthrough Prize in Life Sciences for discoveries leading to the development of a class of drugs that are now widely used in the treatment of Type 2 diabetes and obesity.
9
Spain:
Daniel Drucker was the first to identify GLP-1 and discusses future accessibility of weight loss medications.
5